PharmaNeuroBoost initiates a Proof-of-Concept study in Schizophrenia with its second product, PNB02, after securing substantial funding for innovative biomarker research by IWT
“Our mission at PNB is to significantly improve the treatment of devastating psychiatric disorders like Schizophrenia that is still insufficient”, says CEO, Erik Buntinx, psychiatrist and inventor of PNB02. “Thanks to the financial support from the Flemish Agency for Innovation by Science and Technology (IWT)”, Buntinx continues, “PNB is provided with the opportunity to perform functional MRI with the objective to identify bio-markers that optimize the development of new drugs”.
“Taking advantage of the innovative neuro-imaging technologies that are available at the University Hospital Gasthuisberg of Leuven, we can measure very precisely the activity in the different parts of the brain in psychiatric patients, and relate it to the clinical effect of new drug candidates”, says Didier de Chaffoy, PhD en Chief Science Officer at PNB, “all in support to the development of better treatments for psychiatric and neurological disorders”.
PNB02 is the second drug development project that is initiated by PNB. PNB01 is at present in phase 3 clinical development in the United States of America and Canada for the treatment of Major Depression.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.